Remove 2018 Remove Diagnostic Remove Disease
article thumbnail

Diagnosing Pediatric Crohn Disease With Radiomic and Clinical Data

Imaging Technology

milla1cf Wed, 08/02/2023 - 19:58 August 2, 2023 — An accepted manuscript published in the American Journal of Roentgenology (AJR) found that deploying a radiomic-based model with T2-weighted MRI data could increase diagnostic accuracy for pediatric Crohn disease (CD). Dillman et al.’s

article thumbnail

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Imaging Technology

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

ECR: What makes small ovarian lesions light up like a lightbulb?

AuntMinnie

Part of the trial's overarching work includes predicting whether complete debulking surgery could be achieved and whether or not DW-MRI could be a cost-effective method in the diagnostic work-up of advanced ovarian cancer. that every visible disease has to be removed surgically," Lahaye said. Complete debulking is very important.

MRI 110
article thumbnail

Terran Biosciences Receives FDA Clearance for NM-101, the Industry’s First Software for the analysis of Neuromelanin-sensitive MRI

Imaging Technology

While neuromelanin was first described in the 19 th century, researchers have elucidated its possible role as a biomarker for neurological disorders such as Parkinson’s disease in the last two decades. Cassidy, “it allows us to obtain potentially useful adjunctive information about many other diseases such as Alzheimer’s disease, and PTSD.”

article thumbnail

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

Imaging Technology

POSLUMA is widely available through 36 radiopharmacies in the national network of Blue Earth Diagnostics’ commercial U.S. The addition of POSLUMA to the highly respected NCCN Guidelines is a major milestone for Blue Earth Diagnostics,” said David E. Chief Medical Officer of Blue Earth Diagnostics. Teoh, MBBS, MRCP, FRCR, D.Phil.,

article thumbnail

Racial disparities found in outpatient imaging for cognitive impairment

AuntMinnie

CHICAGO – Black patients receive fewer MRI scans for Alzheimer’s disease diagnosis and undergo imaging at an older age than other racial groups, according to research presented November 27 at RSNA 2023. Additionally, new treatments have recently become available for Alzheimer’s disease that can potentially slow the rate of decline.

Imaging 119
article thumbnail

Synoptic Reporting Improves Pretreatment CT for Advanced Ovarian Cancer

Imaging Technology

s AJR accepted manuscript included 205 patients (median age, 65 years) who underwent contrast-enhanced abdominopelvic CT before primary treatment for advanced ovarian cancer from June 1, 2018 to January 31, 2022. Andrieu et al.’s A total of 128 reports generated before March 31, 2020 used a simple structured report (i.e.,